Celgene to acquire Pharmion

December 1, 2007
Oncology NEWS International, Oncology NEWS International Vol 16 No 12, Volume 16, Issue 12

Celgene to acquire Pharmion

SUMMIT, New Jersey—Celgene Corporation and Pharmion Corporation (Boulder, Colorado) have signed a definitive merger agreement by which Celgene will acquire all of the outstanding shares of Pharmion common stock. The acquisition furthers Celgene's strategy to become a global leader in the hematology/oncology field, the company said in a news release. The transaction brings together three cancer therapies: Celgene's Revlimid (lenalidomide) and Thalomid (thalidomide), and Pharmion's Vidaza (azacitadine).

Related Content:

News